Dermatological Drugs - Mauritius

Mauritius

The Dermatological Drugs market in Mauritius is expected to achieve a revenue of US$1.48m in 2024.
This projection indicates a steady growth rate of 6.52% annually from 2024 to 2029, resulting in a market volume of US$2.03m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with an estimated value of US$11,670.00m in 2024.
Mauritius is witnessing a surge in demand for dermatological drugs due to the increasing prevalence of skin conditions among its population.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for dermatological drugs in Mauritius has been steadily increasing in recent years.

Customer preferences: Mauritian customers are becoming more aware of the importance of skincare and are increasingly seeking treatment for various skin conditions. The rise in disposable income has also contributed to the increase in demand for dermatological drugs.

Trends in the market: The dermatological drugs market in Mauritius is expected to continue growing due to the increasing prevalence of skin diseases and the rising demand for cosmetic procedures. Topical drugs such as creams and ointments are the most commonly used dermatological drugs in Mauritius, followed by systemic drugs such as tablets and capsules. The market is dominated by multinational pharmaceutical companies, although there is a growing presence of local companies.

Local special circumstances: Mauritius has a tropical climate, which makes the population more susceptible to skin diseases such as acne, eczema, and psoriasis. Additionally, the country has a large tourism industry, which has led to an increase in demand for cosmetic procedures such as botox and dermal fillers.

Underlying macroeconomic factors: Mauritius has a stable economy with a growing middle class, which has contributed to the increase in demand for dermatological drugs. The government has also implemented policies to promote healthcare and increase access to medication, which has further boosted the market. However, the market is still hindered by the high cost of some dermatological drugs and the lack of insurance coverage for certain treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.